Clinical Trial ProgressSensorion has completed enrollment for its Phase 2a study of SENS-401, indicating progress in their clinical trial efforts.
Financial StabilitySensorion ended the year with EUR77m in cash after two successful funding rounds, ensuring financial stability.
Product DifferentiationSensorion is differentiated from competitors in the hearing loss gene-therapy space by targeting a younger patient population, which is ideal for a meaningful impact on speech development via SENS-501 treatment.